We know that HER2-positive breast cancer has the potential to behave more aggressively, and it has a higher risk of returning post-treatment. Historically, that was something that we could only lament ...

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.

Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.

Breast cancers are ER-positive, HER2-positive, or triple negative. The type of breast cancer you have determines the type of medication you take. Learn more from experts at WebMD.

T-DXd approved in metastatic HR-positive, HER2-low/ultralow disease following endocrine therapy. ... The FDA has specified use of the Ventana Pathway anti-HER2/neu (4B5) antibody assay.

Proper treatment will be determined, in part, by the kind of cancer you have. Breast cancer can be classified as invasive or noninvasive. Types of breast cancer include invasive ductal carcinoma (IDC) ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

HER2-positive breast cancer is different from other breast cancer types, so your treatment won’t necessarily be the same as someone else who has a different form of breast cancer.

In patients with MBC and HER2/neu overexpression or HER2 amplification, a combination of the humanized anti-HER2 monoclonal antibody trastuzumab and a taxane, with or without carboplatin, has been ...

Highlights in HER2+ breast cancer from SABCS 2023 include data from the HER2CLIMB-02 trial of tucatinib plus T-DM1 and a 9-year follow-up of the KATHERINE trial, as discussed by Dr Harold Burstein.

Today, the FDA granted a label expansion approval for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody, a companion diagnostic, to identify patients with HR-positive, HER2 ...

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s ...